Although these early preclinical tests demonstrated the possibility of modifying CXCR4 and/or CCR5 to prevent or treat HIV infections, the labor-intensive nature of protein engineering and limited scalability have restricted their broad application 144. This evidence concerns the gene CCR5 and HIV infectious disease.